|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:drug
|
|
gptkbp:activities
|
inhibits reuptake of norepinephrine and dopamine
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Aptensio_XR
|
|
gptkbp:class
|
gptkb:drug
|
|
gptkbp:clinical_trial
|
NC T02212345
NC T02212346
NC T02212347
|
|
gptkbp:contraindication
|
gptkb:sneaker
heart problems
history of substance abuse
|
|
gptkbp:counseling_services
|
keep out of reach of children
do not crush or chew
monitor for mood changes
take as prescribed
report any heart problems
|
|
gptkbp:current_use
|
ADD
ADHD
|
|
gptkbp:dosage_form
|
gptkb:beer
|
|
gptkbp:form
|
extended-release capsule
|
|
gptkbp:has_ability
|
15 mg
30 mg
22.5 mg
7.5 mg
3.75 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aptensio XR
|
|
gptkbp:ingredients
|
gptkb:drug
|
|
gptkbp:interacts_with
|
gptkb:warfarin
antidepressants
MAO inhibitors
antihypertensives
anticonvulsants
|
|
gptkbp:is_available_in
|
gptkb:Australia
gptkb:UK
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:is_used_for
|
treatment of ADHD
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Neos_Therapeutics
|
|
gptkbp:marketed_as
|
gptkb:2015
|
|
gptkbp:packaging
|
gptkb:beer
|
|
gptkbp:previous_name
|
gptkb:drug
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:side_effect
|
anxiety
headache
nausea
decreased appetite
insomnia
|
|
gptkbp:storage
|
room temperature
away from moisture
away from heat
|